CIA

6-BENZO[1,3]DIOXOL-5-YL-2-METHYL-2,3,6,7,12,12A-HEXAHYDRO-PYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE


View summary at Ligand Expo



Chemical Component Summary

Name6-BENZO[1,3]DIOXOL-5-YL-2-METHYL-2,3,6,7,12,12A-HEXAHYDRO-PYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE
SynonymsTADALAFIL; CIALIS
Identifiersn/a
FormulaC22 H19 N3 O4
Molecular Weight389.40
TypeNON-POLYMER
Isomeric SMILESCN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c5ccc6OCOc6c5)C1=O
InChIInChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
InChIKeyWOXKDUGGOYFFRN-IIBYNOLFSA-N

Chemical Details

Formal Charge0
Atom Count48
Chiral Atom Count2
Bond Count53
Aromatic Bond Count15

Drug Info: DrugBank

DrugBank IDDB00820 
NameTadalafil
Groups
  • approved
  • investigational
DescriptionTadalafil is an orally administered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Cialis. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadalafil's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Cialis nickname of the "weekend pill." This longer half-life also is the basis of current investigation for tadalafil's use in pulmonary arterial hypertension as a once-daily therapy.
Synonyms
  • Tadalafilo
  • (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
  • Tadalafil
  • (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
Brand Names
  • Alyq
  • Teva-tadalafil
  • PMS-tadalafil
  • Act Tadalafil
  • Apo-tadalafil
IndicationUsed for the treatment of erectile dysfunction.
Categories
  • Antihypertensive Agents
  • Antihypertensives for Pulmonary Arterial Hypertension
  • Carbolines
  • Cardiovascular Agents
  • Cytochrome P-450 CYP3A Substrates
ATC-Code
  • G04BE08
  • C02KX52
CAS number171596-29-5

Drug Targets

NameTarget SequencePharmacological ActionActions
cGMP-specific 3',5'-cyclic phosphodiesteraseMERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKAT...unknowninhibitor
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AMAASRLDFGEVETFLDRHPELFEDYLMRKGKQEMVEKWLQRHSQGQGALG...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682